PEG-glutaminase/diazo-oxo-L-norleucine - New Medical Enzymes AG
Alternative Names: Diazo-oxo-L-norleucine/PEG-glutaminase; Diazooxonorleucine/PEG-glutaminase; DON/PEG-PGA; GlutaDON; PEG-glutaminase/diazooxonorleucine; PEG-PGA/DONLatest Information Update: 08 Aug 2019
At a glance
- Originator New Medical Enzymes AG
- Class Antineoplastics; Azo compounds; Glutaminase; Norleucines
- Mechanism of Action DNA synthesis inhibitors; Glutamine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
Most Recent Events
- 08 Aug 2019 No development reported - Phase-I/II for Colorectal cancer (Metastatic disease) in Germany (IV)
- 08 Aug 2019 No development reported - Phase-I/II for Gastric cancer in Germany, Poland (IV)
- 08 Aug 2019 No development reported - Phase-I/II for Non-small cell lung cancer in Poland, Germany (IV)